Skip to main contentAI and Advanced
/
ACUTAAS · NSEBSE SENSEX74,781.76-0.16%BSE |
NIFTY 5023,398.1-0.34%NSE |
NIFTY BANK56,606.55+0.24%NSE |
NIFTY IT28,921.5+0.11%NSE |
NIFTY AUTO27,304.5-0.86%NSE |
NIFTY FMCG45,053.75-0.29%NSE |
NIFTY PHARMA26,532.4-0.09%NSE |
NIFTY 50022,866.5-0.37%NSE |
AC
NSE · Equity shares · Chemical Manufacturing-67.70 · -1.96%
Acutaas Chemicals ACUTAAS
NSE:INR 3,383.7
BSE:INR 3,372.25
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ACUTAAS
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 3,451.4
Day rangeINR 3,350 — INR 3,488
52-week rangeINR 1,263.95 — INR 3,740
Volume3.25 L
Market cap26,606.93
P/E74.76
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,339.37
Net Income (INR Cr)356.26
Rev Growth (5 Year %)31.84
EPS Growth (5 Year %)42.39
P/E Ratio74.76
EPS43.37
Research path: Interpret Acutaas Chemicals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ACUTAASAcutaas Chemicals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,983.96 | 1,549.26 | 1,095.9 |
| Other Liabilities Total | 4.59 | 2.55 | 1.32 |
| Common Stock Total | 40.94 | 40.93 | 36.88 |
| Other Equity Total | 1,612.63 | Not available | Not available |
| Other Current Assets Total | 59.95 | Not available | Not available |
| Total Assets | 1,983.96 | 1,549.26 | 1,095.9 |
| Cash | 215.55 | 185.22 | 29.7 |
| Total Equity | 1,653.56 | 1,309.63 | 674 |
| Long Term Investments | 8.42 | 0.56 | 0.2 |
| Total Common Shares Outstanding | 8.19 | 8.19 | 7.38 |
| Tangible Book Valueper Share Common Eq | 188.35 | 152.02 | 82.28 |
| Goodwill Net | 104.34 | 56.8 | 56.8 |
| Total Liabilities | 330.4 | 239.63 | 421.91 |
| Total Debt | 35.6 | 12.94 | 216.65 |
| Short Term Investments | 9.28 | 63.7 | 23.61 |
| Cashand Short Term Investments | 224.83 | 248.93 | 53.31 |
| Total Receivables Net | 365.16 | 348.36 | 279.19 |
| Notes Payable/Short Term Debt | 26.49 | 8.18 | 72.59 |
| Deferred Income Tax | 28.71 | 19.63 | 13.02 |
| Accounts Receivable-Trade Net | 362.56 | 290.49 | 206.35 |
| Property/Plant/Equipment Total-Net | 965.64 | 635.6 | 485.48 |
| Minority Interest | 57.19 | 10.45 | 8.76 |
| Total Current Liabilities | 230.81 | 202.25 | 285.17 |
| Total Inventory | 231.32 | 191.83 | 160.89 |
| Accounts Payable | 153.91 | 156.05 | 134.61 |
| Other Currentliabilities Total | 50.42 | 38.02 | 47.56 |
| Total Long Term Debt | 9.11 | 4.75 | 113.64 |
| Intangibles Net | 7.19 | 8.28 | 10.31 |
| Other Long Term Assets Total | 17.1 | 4.05 | 46.76 |
| Note Receivable-Long Term | 0 | 52.34 | 0.55 |
| Total Current Assets | 881.27 | 791.64 | 495.81 |
| Capital Lease Obligations | 9.11 | 4.75 | 0.2 |
| Accumulated Depreciation Total | Not available | -79.25 | -54.59 |
| Long Term Debt | Not available | 0 | 113.44 |
| Prepaid Expenses | Not available | 2.52 | 2.42 |
| Additional Paid-In Capital | Not available | 813.15 | 325.69 |
| Retained Earnings(Accumulated Deficit) | Not available | 455.54 | 311.43 |
| Property/Plant/Equipment Total-Gross | Not available | 584.56 | 414.65 |
| Current Portof LT Debt/Capital Leases | Not available | Not available | 30.42 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.25
Price to Sale Ratio19.87
Growth
Debt 5Yr CAGR %-23.59
Margins
Operating Margin 12m34.54
Operating Margin 5y Avg22.29
Net Profit Margin 12m26.5
Net Profit Margin 5y17.16
Yield
Dividend Yield %0.08
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk49.66
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions6
Strong Sell count0
Sell count1
Hold count0
Buy count3
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Asian Paints | INR 2,749 | 2.64 L | 58.09 | — |
| Solar Industries India | INR 18,560 | 1.68 L | 99.61 | — |
| Pidilite Industries | INR 1,671 | 1.70 L | 64.76 | — |
| SRF | INR 2,626 | 77,841.16 | 44.57 | — |
| Linde India | INR 7,105 | 61,033.66 | 110.53 | — |
Shareholding
Ownership
- Promoter
- 32.66%
- FII
- 21.61%
- MF
- 14.17%
- Other
- 31.56%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Number of shareholders of Acutaas Chemicals Ltd – NSE:ACUTAAS - TradingViewMarket news · 4 Jun 2026, 6:34 am
Number of shareholders of Acutaas Chemicals Ltd – NSE:ACUTAAS TradingView
Acutaas Chemicals Ltd is Rated Strong Buy - Markets MojoMarket news · 3 Jun 2026, 4:40 pm
Acutaas Chemicals Ltd is Rated Strong Buy Markets Mojo
Broad-Based Technical Strength Lifts Acutaas Chemicals Ltd to 52-Week High of Rs 3189.5 - Markets MojoMarket news · 3 Jun 2026, 2:46 am
Broad-Based Technical Strength Lifts Acutaas Chemicals Ltd to 52-Week High of Rs 3189.5 Markets Mojo
Acutaas Chemicals Q4 FY26: Stellar Performance Drives 111% Profit Surge - Markets MojoMarket news · 3 Jun 2026, 2:27 am
Acutaas Chemicals Q4 FY26: Stellar Performance Drives 111% Profit Surge Markets Mojo
Acutaas Chemicals Ltd Hits All-Time High of Rs 3,189.5 as Momentum Builds Across Timeframes - Markets MojoMarket news · 2 Jun 2026, 11:01 am
Acutaas Chemicals Ltd Hits All-Time High of Rs 3,189.5 as Momentum Builds Across Timeframes Markets Mojo
Acutaas Chemicals - FIIs bet on high-growth smallcaps: 14 stocks rally up to 225% in 5 months, 6 turn multibaggers - The Economic TimesMarket news · 1 Jun 2026, 4:32 pm
Acutaas Chemicals - FIIs bet on high-growth smallcaps: 14 stocks rally up to 225% in 5 months, 6 turn multibaggers The Economic Times
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.2.5000 per share(50%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.5000 per share(30%)Final Dividend
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for Acutaas Chemicals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Acutaas Chemicals Limited, formerly Ami Organics Limited, is an India-based company, which is engaged in the manufacturing of pharma intermediates and specialty chemicals. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. It manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It has developed and commercialized over 610 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas.
Company facts
- Industry
- Chemical Manufacturing
- Sector
- Chemical Manufacturing
- NSE Code
- ACUTAAS
- BSE Code
- 543349
Questions
Stock FAQ
What is the symbol and ISIN of Acutaas Chemicals?
Acutaas Chemicals has the symbol ACUTAAS and ISIN - INE00FF01025.
What is the current price of Acutaas Chemicals?
Acutaas Chemicals is currently trading at INR 3,383.70.
What are the year high and year low of Acutaas Chemicals?
Acutaas Chemicals has a year high of INR 3,740.00 and a year low of INR 1,263.95.
What is the market capitalization of Acutaas Chemicals?
Acutaas Chemicals has a market capitalization of INR 26,606.93 crore.
What is the P/E ratio of Acutaas Chemicals?
Acutaas Chemicals has a P/E ratio of 74.76.
What is the dividend yield of Acutaas Chemicals?
Acutaas Chemicals has a dividend yield of 0.08%.
How is the financial performance of Acutaas Chemicals based on revenue, net income, and EPS?
Acutaas Chemicals has revenue of INR 1,339.37 crore, net income of INR 356.26 crore, and EPS of INR 47.00.
What is the book value of Acutaas Chemicals?
Acutaas Chemicals has a book value of NA.
What is the debt-to-equity ratio of Acutaas Chemicals?
Acutaas Chemicals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Acutaas Chemicals?
Acutaas Chemicals has a price-to-book ratio of NA and a price-to-sales ratio of 19.87.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.